Three million prescriptions in about five months has reset the GLP-1 race. Novo Nordisk said its oral Wegovy hit that mark in a June 7 release and highlighted the figure at the American Diabetes Association meeting. The milestone helps explain why Novo and Eli Lilly are repositioning for seniors now that Medicare will cover GLP-1 weight-loss drugs in 2026, moving millions of beneficiaries from full out-of-pocket costs to a modest monthly copay and changing the commercial calculus for both firms.

30 percent. That's the share Novo Nordisk said oral Wegovy now represents of total Wegovy prescriptions, a figure the company and analyst notes tied to IQVIA data used to sketch the launch's pace. Novo reported more than 80 percent of patients taking the Wegovy pill were new to GLP-1 therapy, an indicator that the oral format is pulling a fresh cohort into treatment rather than simply switching injectables to pills.

Launch math sets the benchmark

The raw launch numbers underline how fast the market can change. Novo said Wegovy surpassed 3 million U.S. prescriptions and that it reached its second million in ten weeks after taking 12 weeks to get the first million. By comparison, Citi analysts tracking IQVIA estimated Eli Lilly's oral GLP-1, Foundayo, had recorded roughly 16,982 prescriptions as of early June, about 17,000 scripts since its April debut. IQVIA data also showed that at the same eight-week point in its own launch cycle, Novo's oral Wegovy had hit 73,544 prescriptions.

Those contrasts matter because they set the benchmark competitors now chase. The speed of uptake for an oral semaglutide formulation has encouraged rivals, but it also raises pressure to execute on distribution, pricing, and prescriber education. Market research firms report the oral launch is drawing in primary care prescribers and patients who previously didn't seek pharmacological obesity treatment.

Messaging shifts for seniors and prescribers

Both companies used the American Diabetes Association meeting to press competing narratives aimed at older patients and the clinicians who treat them. Novo Nordisk's chief executive Mike Doustdar argued that the Wegovy high-dose portfolio offers benefits beyond weight loss that are relevant to older adults, including cardiovascular, kidney and liver advantages, an argument Novo made at the ADA event and in its company material. Eli Lilly's chief executive Dave Ricks framed Foundayo's advantage as convenience, telling CNBC the pill can be taken with food and other medicines at any time of day. Ricks contrasted that with oral semaglutide's dosing requirement of taking it on an empty stomach and waiting 30 minutes before eating or taking other drugs, a practical difference that matters for seniors on multiple daily medicines.

Mastheads

Both executives told CNBC they're preparing outreach to raise awareness of Medicare coverage and to position their products for beneficiaries once coverage begins in 2026. The ADA conference featured visible marketing from both firms, and both are gearing up targeted information campaigns for seniors to explain the new copay arrangement.

Market trackers paint a broader picture of demand. Spherix Global Insights told analysts that in the first four weeks of oral Wegovy availability, 73 percent of surveyed primary care physicians had prescribed it and over 98 percent of those who had not yet prescribed planned to do so within six months. At the same time, weekly GLP-1 script volumes saw a short-term dip, with total GLP-1 prescriptions down about 5.7 percent week-over-week for the week of June 1, according to IQVIA-based tracking cited by analysts.

That suggests initial launch enthusiasm can coexist with short-term volatility in overall script volumes.

The competitive battleground is now as much about commercial strategy as about head-to-head clinical claims. Novo is emphasising the broader cardiometabolic profile of semaglutide-based therapy and investing in physician and patient advertising. Lilly is leaning on ease of use and the practical fit of Foundayo into patients' daily pill routines. Both companies are preparing to capitalise on Medicare's decision to make GLP-1 weight-loss drugs more affordable for beneficiaries.

For clinicians and health systems the calculus will involve more than price. Prescribers will weigh tolerability, convenience, the evidence base for additional organ-protective effects, and how each therapy fits existing medication schedules for older patients. For payers and policymakers, the rapid adoption of oral options changes budget dynamics and the distribution of cost between manufacturers, insurers, and patients.

Related Articles

Medicare's coverage change takes effect in 2026, when beneficiaries will be eligible for a monthly copay arrangement that both companies are preparing to promote. Watch for pricing announcements, targeted outreach to seniors, and upcoming CMS guidance on implementation early in 2026.

This article was created with AI assistance.